Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors inside the central anxious process, conolidine modulates alternate molecular targets. A Science Innovations examine found that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://tinaq295ckr5.blogdal.com/profile